Skip to main content
. 2019 Jan 30;38(21):4002–4014. doi: 10.1038/s41388-019-0680-2

Fig. 3.

Fig. 3

Immunofluorescence staining of PDCs for clinical markers found in the patient’s original CM tumor, and astrocyte marker GFAP. a Based on the patient pathology report, the tumorigenic CM04-PDC had positive staining of diagnostic markers consistent with a SCLC diagnosis. b Non-tumorigenic CM01-PDC, which was derived from a breast cancer CM, was negative for all of the patient’s clinical markers. Pathological scoring of these markers for all PDCs can be found in Supplementary Table 2